Catalent has signed an agreement for the acquisition of full-service specialty Contract Development and Manufacturing Organization (CDMO) Metrics Contract Services for $475m from Mayne Pharma. 

The takeover of Metrics will bolster the expertise of Catalent in the development of integrated oral solid formulation, production and packaging to aid customers in streamlining and expediting their programmes. 

It will also aid in expanding the capacity of Catalent to manage highly potent compounds.

Metrics has a 333,000ft² facility in Greenville, North Carolina, US.

This plant offers complete expertise to expedite and de-risk customer programmes from the initial development stage to commercial launch using a simplified one-site solution. 

Over $100m was invested in the facility in the last five years and currently comprises 16 production suites, of which 11 are equipped to manage highly potent compounds. 

It also has two packaging lines that can accommodate a wide range of development and commercial supply programmes. 

Furthermore, the plant has a manufacturing capacity of more than one billion oral solid dose units annually.

Following the acquisition, the Greenville facility of Metrics will be integrated into the oral development and manufacturing network of Catalent. 

The network comprises sites for the production of large-scale and controlled release oral solids in Winchester, Kentucky, development and manufacturing of softgel in St Petersburg, Florida, as well as other facilities with bioavailability enhancement technologies and platforms for oral solids production.

In addition, Catalent and Mayne Pharma agreed on a long-term supply agreement under which the Greenville facility will progress to produce various products of the latter. 

Catalent Pharma & Consumer Health segment group president Dr Aris Gennadios said: “This acquisition will further expand Catalent’s ability to meet our customers’ expectations in fast-growing areas of the business and patient need. 

“The experienced team and consistently improved, state-of-the-art facility in Greenville will provide Catalent’s customers with immediate, fit-for-scale capacity for in-demand highly potent drugs and other oral solid small-to-mid-size batch needs.”  

Subject to necessary closing conditions, the deal is anticipated to conclude before the end of this calendar year.